11:57 AM
 | 
Dec 01, 2017
 |  BioCentury  |  Finance

Semma prepares to deliver

How Semma will continue its transition from lab to clinic with a $114M series B

After scaling up its beta cell generation protocol and developing a cell delivery technology, Semma Therapeutics Inc. has raised a $114 million series B round that will enable the company to bring its Type I diabetes cell therapy through clinical proof of concept.

Eight Roads Ventures and Cowen Healthcare Investments led the B round, which closed on Nov. 30. Fellow new investors ORI Healthcare Fund, Wu Capital, 6 Dimensions Capital and SinoPharm Capital also participated alongside existing investors MPM Capital, F-Prime Capital...

Read the full 394 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury

Article Purchase

$150 USD
More Info >